Kuntze C E, Ebels T, Eijgelaar A, Homan van der Heide J N
Department of Thoracic and Cardiovascular Surgery, University Hospital Groningen, The Netherlands.
Lancet. 1989 Mar 11;1(8637):514-7. doi: 10.1016/s0140-6736(89)90065-2.
In 434 operations for valvular heart disease, patients were randomised to receive Björk-Shiley, Edwards-Duromedics, or Medtronic-Hall mechanical prostheses. At a median follow-up time of 37.5 months there were no differences in hazard of death or non-embolic events. In the first six postoperative months the incidence of thromboembolism was about the same for the three valves. Subsequently, however, the incidence of thromboembolism for the Edwards-Duromedics valve was 3.9 times higher than for the Björk-Shiley valve, and for the Medtronic-Hall valve 2.6 times higher than for the Björk-Shiley valve.
在434例心脏瓣膜病手术中，患者被随机分配接受Björk-Shiley、Edwards-Duromedics或Medtronic-Hall机械瓣膜假体。在中位随访时间37.5个月时，死亡或非栓塞事件的风险没有差异。术后头六个月，三种瓣膜的血栓栓塞发生率大致相同。然而，随后，Edwards-Duromedics瓣膜的血栓栓塞发生率比Björk-Shiley瓣膜高3.9倍，Medtronic-Hall瓣膜的血栓栓塞发生率比Björk-Shiley瓣膜高2.6倍。
